Twist Bioscience Reports Preliminary Q1 Revenue Ahead of Guidance
Summary
Twist Bioscience reported preliminary Q1 fiscal 2026 revenue of $103.7 million, surpassing its guidance and demonstrating strong growth in its core segments.
Key Events
-
Preliminary Q1 Fiscal 2026 Revenue Exceeds Guidance
Twist Bioscience reported preliminary, unaudited revenue of approximately $103.7 million for the first quarter ended December 31, 2025, surpassing its previous guidance of $100 million to $101 million.
-
Strong Revenue Growth Across Segments
Total revenue grew 17% year-over-year. DNA Synthesis and Protein Solutions revenue increased by 27% to $51.1 million, and NGS Applications revenue reached $52.6 million, growing 18% excluding one large customer.
-
CEO Highlights Operational Momentum
CEO Emily M. Leproust noted the strong start to the fiscal year and expressed encouragement regarding overall revenue growth and continued momentum in both the DNA Synthesis and Protein Solutions and NGS Applications segments.
Analysis
Twist Bioscience announced preliminary first-quarter fiscal 2026 revenue of $103.7 million, exceeding its own guidance of $100-$101 million. This indicates a strong start to the fiscal year with solid growth across its key segments, particularly DNA Synthesis and Protein Solutions, and NGS Applications. While these results are unaudited and preliminary, the positive performance ahead of expectations could instill investor confidence regarding the company's operational momentum.
At the time of this filing, TWST was trading at $35.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $23.30 to $55.33. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.